AbbVie’s promised rheumatoid arthritis blockbuster upadacitinib hits its marks in another PhIII — this time without any deaths
AbbVie $ABBV has posted another positive batch of Phase III data on its JAK1 inhibitor upadacitinib, hitting the primary and key secondary endpoints in their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
